Foamix Pharmaceuticals Ltd. Closes Its $69 Million Public Offering of Ordinary Shares
Foamix Pharmaceuticals Ltd. closed its follow-on public offering. A total of 7,419,353 ordinary shares were sold at a price to the public of $9.30 per share. Prior to closing, the underwriters fully exercised their option to purchase 967,741 additional ordinary shares. The net proceeds from the sale of shares, after deducting underwriting discounts, commissions and other estimated offering expenses, will be approximately $64.2 million.
Barclays Capital Inc., Cowen and Company, LLC and Guggenheim Securities, LLC acted as book-running managers for the offering. Oppenheimer & Co. Inc. acted as co-manager.
The offering of these securities has been made only by means of a written prospectus. A copy of the prospectus related to the offering may be obtained from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 1 (888) 603-5847, or by emailing: Barclaysprospectus@broadridge.com; Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 631-274-2806, fax: 631-254-7140; or Guggenheim Securities, LLC, 330 Madison Avenue, 8th Floor, New York, NY 10017, Attention: Equity Syndicate Department, telephone: (212) 518-9349 or by emailing: GSEquityProspectusDelivery@guggenheimpartners.com.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission.